Literature DB >> 24418808

The changing role of imaging in clinical care.

Rahul Aggarwal1, John Kurhanewicz2.   

Abstract

Considerable developments in prostate cancer in 2013 have emerged from the imaging field. Hyperpolarized 13C-MRI can monitor metabolic activity to identify high-grade disease and treatment response, and novel PET radiotracers might identify distinct subsets of patients with advanced disease. These examples highlight the progress made at all stages of care.

Entities:  

Mesh：

Year:  2014        PMID： 24418808      PMCID： PMC4057014          DOI： 10.1038/nrurol.2013.319

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  10 in total

Review 1.  Molecular imaging of prostate cancer with PET.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2013-10       Impact factor: 10.057

2.  The 19th annual Prostate Cancer Foundation scientific retreat.

Authors:  Guneet Walia; Kenneth J Pienta; Jonathan W Simons; Howard R Soule
Journal:  Cancer Res       Date:  2013-03-27       Impact factor: 12.701

Review 3.  Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis.

Authors:  Laura Evangelista; Fabio Zattoni; Andrea Guttilla; Giorgio Saladini; Filiberto Zattoni; Patrick M Colletti; Domenico Rubello
Journal:  Clin Nucl Med       Date:  2013-05       Impact factor: 7.794

4.  Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Authors:  Juan Miguel Mosquera; Himisha Beltran; Kyung Park; Theresa Y MacDonald; Brian D Robinson; Scott T Tagawa; Sven Perner; Tarek A Bismar; Andreas Erbersdobler; Rajiv Dhir; Joel B Nelson; David M Nanus; Mark A Rubin
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

5.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

Authors:  Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

6.  Prostate cancer: can multiparametric MR imaging help identify patients who are candidates for active surveillance?

Authors:  Baris Turkbey; Haresh Mani; Omer Aras; Jennifer Ho; Anthony Hoang; Ardeshir R Rastinehad; Harsh Agarwal; Vijay Shah; Marcelino Bernardo; Yuxi Pang; Dagane Daar; Yolanda L McKinney; W Marston Linehan; Aradhana Kaushal; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Radiology       Date:  2013-03-06       Impact factor: 11.105

Review 7.  Prostate cancer: role of SPECT and PET in imaging bone metastases.

Authors:  Mohsen Beheshti; Werner Langsteger; Ignac Fogelman
Journal:  Semin Nucl Med       Date:  2009-11       Impact factor: 4.446

8.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study.

Authors:  Philippe Puech; Olivier Rouvière; Raphaele Renard-Penna; Arnauld Villers; Patrick Devos; Marc Colombel; Marc-Olivier Bitker; Xavier Leroy; Florence Mège-Lechevallier; Eva Comperat; Adil Ouzzane; Laurent Lemaitre
Journal:  Radiology       Date:  2013-04-11       Impact factor: 11.105

9.  A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

Authors:  Joseph R Osborne; David A Green; Daniel E Spratt; Serge Lyashchenko; Shoaib B Fareedy; Brian D Robinson; Bradley J Beattie; Manu Jain; Jason S Lewis; Paul Christos; Steven M Larson; Neil H Bander; Douglas S Scherr
Journal:  J Urol       Date:  2013-10-14       Impact factor: 7.450

10.  Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate.

Authors:  Sarah J Nelson; John Kurhanewicz; Daniel B Vigneron; Peder E Z Larson; Andrea L Harzstark; Marcus Ferrone; Mark van Criekinge; Jose W Chang; Robert Bok; Ilwoo Park; Galen Reed; Lucas Carvajal; Eric J Small; Pamela Munster; Vivian K Weinberg; Jan Henrik Ardenkjaer-Larsen; Albert P Chen; Ralph E Hurd; Liv-Ingrid Odegardstuen; Fraser J Robb; James Tropp; Jonathan A Murray
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956
  10 in total
  2 in total

1.  Chrebp regulates the transcriptional activity of androgen receptor in prostate cancer.

Authors:  Xue-Lei Wang; Xiao-Fei Wen; Rong-Bing Li; Bin Liu; Guang-Ming Qiu; Ji-Ling Wen; Yue-Min Wang
Journal:  Tumour Biol       Date:  2014-05-21

2.  Direct and cost-efficient hyperpolarization of long-lived nuclear spin states on universal (15)N2-diazirine molecular tags.

Authors:  Thomas Theis; Gerardo X Ortiz; Angus W J Logan; Kevin E Claytor; Yesu Feng; William P Huhn; Volker Blum; Steven J Malcolmson; Eduard Y Chekmenev; Qiu Wang; Warren S Warren
Journal:  Sci Adv       Date:  2016-03-25       Impact factor: 14.136
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.